Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 3—March 2011

Synopsis

Q Fever in France, 1985–2009

Diane Frankel, Hervé Richet, Aurélie Renvoisé, and Didier RaoultComments to Author 
Author affiliations: Author affiliation: Université de la Méditerranée, Marseille, France

Main Article

Table 1

Serum samples tested for Q fever, by year, France*

Year No. positive/
no. tested (%) No. positive
Acute disease Chronic disease
1985 239/2,290 (10.4) 22 8
1986 518/3,464 (15.0) 37 8
1987 767/4,361 (17.6) 52 12
1988 706/3,403 (20.7) 49 12
1989 1,316/4,258 (30.9) 40 18
1990 1,621/4,720 (34.3) 92 22
1991 1,737/5,028 (34.5) 112 20
1992 2,011/5,249 (38.3) 89 29
1993 1,815/7,020 (25.9) 76 26
1994 1,472/7,222 (20.4) 102 24
1995 1,359/6,171 (22.0) 73 34
1996 1,326/7,101 (18.7) 116 28
1997 1,683/7,050 (23.9) 70 35
1998 1,420/7,340 (19.3) 140 37
1999 1,537/8,296 (18.5) 199 32
2000 1,460/8,444 (17.3) 135 32
2001 1,589/8,974 (17.7) 167 38
2002 2,029/10,639 (19.1) 224 55
2003 2,094/10,588 (19.8) 242 52
2004 2,544/10,742 (23.7) 360 70
2005 2,514/10,597 23.7) 199 100
2006 2,010/7,891 (25.5) 266 237
2007 1,700/5,522 (30.8) 244 278
2008 2,073/10,981 (18.9) 256 263
2009 1,933/12,443 (15.5) 361 205
Total 39,472/179,794 (21.9) 3,723 1,675

*Acute disease, phase II (avirulent bacteria) immunoglobulin (Ig) G titer >200 and phase II IgM titer >50; chronic disease, phase I (virulent bacteria) IgG titer >800.

Main Article

TOP